Edition:
India

Qiagen NV (QIA.DE)

QIA.DE on Xetra

26.13EUR
17 Nov 2017
Change (% chg)

€-0.03 (-0.11%)
Prev Close
€26.16
Open
€26.31
Day's High
€26.44
Day's Low
€26.00
Volume
382,533
Avg. Vol
515,142
52-wk High
€31.52
52-wk Low
€25.41

Latest Key Developments (Source: Significant Developments)

Qiagen NV posts qtrly adjusted EPS $0.32‍​
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Qiagen NV :Qiagen NV - qtrly EPS $0.21; qtrly adjusted EPS $0.32‍​.Qiagen NV - reaffirming 2017 adjusted EPS target of $1.25-1.27 cer before restructuring‍​.Qiagen NV - qtrly net sales $364.0 million versus $338.7 mln‍​.Qiagen NV - qtrly adjusted net sales $364.4 million versus $338.7 million.Qiagen NV - for full-year 2017, Qiagen expects adjusted net sales to grow approximately 7 pct cer.Q3 earnings per share view $0.32, revenue view $363.3 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $1.18, revenue view $1.42 billion -- Thomson Reuters I/B/E/S.  Full Article

Qiagen to return $250 mln to shareholders
Sunday, 14 Aug 2016 

Qiagen NV :Qiagen announces plans to return approximately $250 million to shareholders via synthetic share repurchase proposal.  Full Article

Qiagen says it intends to return capital of $300 mln to shareholders by 2017 end
Friday, 29 Jul 2016 

Qiagen Nv : Intends to return capital of $300 million to shareholders by end of 2017 . Intends to return capital to its shareholders in the additional amount of approximately $200 million by early 2017 .Considering share repurchase program announced on 27th April 2016, total return figure is expected to be approximately $300 million.  Full Article

Qiagen Q2 adjusted earnings per share $0.24
Friday, 29 Jul 2016 

Qiagen Reports Results For Second Quarter Of 2016 : Increased Commitment To Return $300 Million Of Capital To Shareholders By End 2017 . On track for continued acceleration in h2 2016 and achieving targets for full-year 2016 growth in net sales and adjusted eps 2017 . Q2 earnings per share $0.09 . Q2 sales rose 5 percent to $334.4 million .Q2 adjusted earnings per share $0.24.  Full Article

QIAGEN offer for Exiqon completed
Thursday, 23 Jun 2016 

Exiqon A/S : Announcement of the final result of the offer and completion thereof .QIAGEN N.V. intends to apply for delisting of shares of Exiqon and initiate squeeze-out of remaining minority shareholders.  Full Article

MDxHealth grants Qiagen rights to MSP technology
Wednesday, 15 Jun 2016 

MDxHealth SA : Grants Qiagen rights to MSP technology for qiasure methylation test for cervical cancer risk .Has granted a non-exclusive worldwide license for its patented methylation-specific PCR (MSP) technology to Qiagen.  Full Article

Qiagen announces second offer extension for acquisition of shares in Exiqon A/S
Friday, 3 Jun 2016 

Qiagen NV : Qiagen announces second offer extension for the acquisition of shares in Exiqon A/S . Offer is valid as of 19 April 2016 and expires on 20 June 2016 at 23:59 (cet) .Qiagen NV says offer period had been extended on 19 May 2016.  Full Article

CareDx and QIAGEN enter into commercial collaboration
Tuesday, 31 May 2016 

Caredx Inc : Caredx and QIAGEN enter into commercial collaboration to enhance HLA lab experience using Qiaxcel instrumentation and Caredx HLA typing technology .Financial terms of collaboration were not disclosed.  Full Article

Qiagen extends tender offer period for acquisition of Exiqon A/S
Thursday, 19 May 2016 

Qiagen Nv : Extends tender offer period for acquisition of Exiqon A/S offer for DKK 18 per share remains valid until 2 june 2016 .Qiagen extends tender offer period for acquisition of Exiqon A/S.  Full Article

Qiagen NV to conduct an up to US$100 mln share repurchase program
Thursday, 28 Apr 2016 

Qiagen NV:To conduct an up to US$100 million share repurchase program.Repurchase program is scheduled to begin at earliest on April 28, 2016, and to be completed on Dec. 23, 2016, or if upcoming General Meeting of Shareholders to extend authorization to repurchase shares for another year, on Dec. 21, 2017, at latest.  Full Article

BRIEF-Qiagen NV posts qtrly adjusted EPS $0.32‍​

* Qiagen NV - reaffirming 2017 adjusted EPS target of $1.25-1.27 cer before restructuring‍​